Kedcom

Human coagulation factor IX/II/X, the active ingredient in Kedcom, is a coagulation factor concentrate presented as an injectable concentrate for intravenous use. It replaces deficient clotting factors in patients with hemophilia B (factor IX deficiency), prothrombin deficiency (factor II), factor X deficiency, or combined deficiencies of these factors, thereby helping to control and prevent bleeding episodes.

GNH USA supplies Kedcom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide through its global network.

Kedcom is used to treat bleeding disorders that involve deficiencies in the intrinsic and common pathways of the coagulation cascade. - Hemophilia B (Factor IX deficiency): restores factor IX activity to achieve hemostasis and reduce bleeding frequency. - Prothrombin deficiency (Factor II deficiency): replaces missing factor II, supporting clot formation and controlling hemorrhage. - Factor X deficiency: provides factor X to re‑establish the common pathway and stop bleeding. - Combined deficiencies of Factors IX, II, and X: supplies all three factors simultaneously to manage acute bleeding episodes.

Kedcom may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion‑related reactions (e.g., chills, flushing, or mild fever) - Headache - Nausea or vomiting - Mild arthralgia - Transient increase in liver enzymes

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Development of neutralizing inhibitors (antibodies) against the infused factors - Thromboembolic events (e.g., deep vein thrombosis) - Viral transmission risk from plasma‑derived products - Severe hemolysis or disseminated intravascular coagulation

When using Kedcom, clinicians should observe several precautionary measures to ensure safety and efficacy. - Dose adjustment: individualize dosing based on factor activity levels and clinical response. - Monitoring: perform regular coagulation assays (e.g., PT, aPTT, factor activity) to guide therapy. - Allergy assessment: evaluate patients for hypersensitivity to plasma‑derived proteins before infusion. - Inhibitor development: watch for emergence of neutralizing antibodies that may reduce effectiveness. - Pregnancy and lactation: use only when the potential benefit justifies any potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kedcom can interact with other medicines that affect hemostasis or immune response.

Major Interactions (Avoid): - Concurrent use of anticoagulants (e.g., warfarin, direct oral anticoagulants) may diminish clotting effectiveness and increase bleeding risk. - High‑dose factor replacement together with pro‑thrombotic agents can precipitate thrombosis. - Simultaneous administration of other plasma‑derived factor concentrates may increase the risk of inhibitor formation.

Moderate Interactions (Monitor Closely): - Antibiotics such as rifampin that induce hepatic enzymes may alter plasma protein turnover, affecting factor levels. - Immunosuppressive drugs (e.g., rituximab) can modify the immune response to infused factors. - Vaccines administered shortly before or after infusion may enhance the chance of allergic reactions.